Skip to content
Baker Capital StrategiesMARKETS. FILINGS. PERSPECTIVE.
Powered by THEMA

Baker Capital Strategies

Free Registration

Register for access to news, tools, alerts and reports.

THEMA Basic included at launch.

Use at least 8 characters.

SEC Filing · S-8 POS

TOURMALINE BIO INC

SEC Filing

Filed Oct 28, 2025Accepted Oct 28, 2025, 7:08 AM EDTCIK 1827506Accession 0001104659-25-102988
Share

Company context

Tourmaline is a late-stage clinical biotechnology company driven by its mission to develop transformative medicines that establish new standards of care for patients with life-altering inflammatory and immune diseases. Tourmaline’s lead asset is pacibekitug. For more information about Tourmaline and pacibekitug, please visit https://www.tourmalinebio.com or follow us on LinkedIn, X or Bluesky.

Historical securities (1)

Recent company filings

  1. EFFECT filingNov 14, 2025
  2. EFFECT filingNov 14, 2025
  3. 15-12G filingNov 7, 2025
  4. 4 filingOct 28, 2025
  5. 4 filingOct 28, 2025

Document unavailable

This filing is not currently available in the archive. Read it on SEC EDGAR ↗